<?xml version="1.0" encoding="UTF-8"?>
<p id="p0100">Since viral vector-based vaccines could be quickly constructed and used without an adjuvant, development of such vaccines might be possible in SARS-CoV-2 because RBD of S-protein has been identified as a neutralizing epitope [
 <xref rid="bb0510" ref-type="bibr">102</xref>]. So this epitope could be actively pursued for the development of viral vector based vaccines.
</p>
